

Tianxiang Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3209949/publications.pdf>

Version: 2024-02-01

9
papers

680
citations

1040056

9
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

731
citing authors

#	ARTICLE	IF	CITATIONS
1	ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis. <i>Pathology Research and Practice</i> , 2021, 219, 153345.	2.3	9
2	MicroRNA-1251-5p promotes tumor growth and metastasis of hepatocellular carcinoma by targeting AKAP12. <i>Biomedicine and Pharmacotherapy</i> , 2020, 122, 109754.	5.6	19
3	BRD8, which is negatively regulated by miR-876â€“3p, promotes the proliferation and apoptosis resistance of hepatocellular carcinoma cells via KAT5. <i>Archives of Biochemistry and Biophysics</i> , 2020, 693, 108550.	3.0	12
4	Hypoxia-inducible long noncoding RNA NPSR1-AS1 promotes the proliferation and glycolysis of hepatocellular carcinoma cells by regulating the MAPK/ERK pathway. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 886-892.	2.1	17
5	Hypoxiaâ€“induced miRâ€“3677â€“3p promotes the proliferation, migration and invasion of hepatocellular carcinoma cells by suppressing SIRT5. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8718-8731.	3.6	22
6	LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells. <i>Cell Death and Disease</i> , 2020, 11, 95.	6.3	67
7	Hypoxia-induced lncRNA EIF3J-AS1 accelerates hepatocellular carcinoma progression via targeting miR-122â€“5p/CTNND2 axis. <i>Biochemical and Biophysical Research Communications</i> , 2019, 518, 239-245.	2.1	37
8	A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. <i>Molecular Cancer</i> , 2019, 18, 28.	19.2	330
9	LncRNA KTN1-AS1 promotes tumor growth of hepatocellular carcinoma by targeting miR-23c/ERBB2IP axis. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 1140-1147.	5.6	62